AbCellera
also invests · investor profileVancouver · Founded 2012 · 587 employees on LinkedIn · 2 known investors
Find your way into AbCellera
1,916 people in our graph share verified history with the AbCellera team — schools, employers, funds. One of them is your warm intro.
Greg Rudinunlockedknows Kevin Heyries · together at Creative Destruction Lab (overlapped)
×10knows the team · via INSEAD
knows the team · via 5AM Ventures
AbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.
Founders & leadership
AbCellera was founded in 2012 by Carl Hansen and Kevin Heyries.
CH
Carl HanseninCo-founder · Chief Executive Officer
KH
Kevin HeyriesinCo-Founder, Director of Emerging Science and Technology2021–2022Kevin Heyries is a co-founder of AbCellera who led the company's business development efforts and established the T-cell engager program, and has since held business development roles in human genetics, biologics, gene editing, and nucleic acid therapeutics. He holds over 15 years of experience in biotech spanning bench research, company growth, and business strategy.
AB
Andrew BoothinChief Financial Officer
Board
DJ
Doug JanzenBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$83.1M disclosed across 4 rounds · 2017–2020
▶$74.5MraisedMay 2020 · 14 investors · BiotechnologyRule 506(b)
▶$74.5MraisedMay 2020 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Veronique LecaultDirector, Executive Officer
- Michael HaydenDirector
- Andrew BoothExecutive Officer
- Carl HansenExecutive Officer, Director
- Stimart TrynExecutive Officer
- John HamerDirector
- Offering amount
- $74.5M
- Amount sold
- $74.5M
- First sale
- Mar 2020
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$7.7MraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$7.7MraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John HamerDirector
- Veronique LecaultDirector
- Andrew BoothDirector
- Carl HansenExecutive Officer, Director
- Offering amount
- $7.7M
- Amount sold
- $7.7M
- First sale
- Aug 2018
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$50KraisedMar 2018 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedMar 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl HansenExecutive Officer, Director
- Doug JanzenExecutive Officer, Director
- Andrew BoothDirector
- Offering amount
- $484.5K
- Amount sold
- $50K
- First sale
- Mar 2018
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$817.9KraisedApr 2017 · 24 investors · BiotechnologyRule 506(b)
▶$817.9KraisedApr 2017 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Doug JanzenExecutive Officer, Director
- Carl HansenExecutive Officer, Director
- Andrew BoothDirector
- Offering amount
- $863.3K
- Amount sold
- $817.9K
- First sale
- Mar 2017
- Incorporated
- Corporation, British Columbia, Canada, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through AbCellera went on to found or lead other companies.
In the news
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing | PharmExecpharmexec.com · Aug 2026
AbCellera offers up USD 200m in stock to support NK3 menopause antibodyallsci.com · Aug 2026
AbCellera launches $200-million equity offering on heels of strong menopause trial results - The Globe and Mailtheglobeandmail.com · Aug 2026
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - AOLaol.com · Aug 2026Frequently asked questions
- What does AbCellera do?
- AbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.
- Who founded AbCellera?
- AbCellera was founded by Carl Hansen, Kevin Heyries in 2012.
- Who are AbCellera's investors?
- AbCellera's investors include Alpha Wave Global, DCVC (Data Collective).
- How much funding has AbCellera raised?
- AbCellera has disclosed $83.1M raised across 4 rounds.
- Where is AbCellera headquartered?
- AbCellera is headquartered in Vancouver.